Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03057002 · ClinicalTrials.gov registry record
UTSW HP [13-C] Pyruvate Injection in HCM
A clinical trial, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- 7
- Enrollment target
NCT03057002 is a clinical trial that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 7 participants.
The verdict
NCT03057002 has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
Study Summary
The study objective is to identify the earliest changes in energy substrate metabolism in patients with cardiomyopathies (CMP). To achieve this objective, we plan first to test the hypothesis that patients with CMP present focal alterations in myocardial hyperpolarized \[1-13C\]pyruvate flux.
Interventions
- DIAGNOSTIC_TEST Hyperpolarized 13C-Pyruvate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2023-05-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03057002
The ClinicalTrials.gov registry entry for NCT03057002 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hyperpolarized 13C-Pyruvate is the first listed.
NCT03057002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03057002 about?
NCT03057002 is a clinical study titled "UTSW HP [13-C] Pyruvate Injection in HCM". The study objective is to identify the earliest changes in energy substrate metabolism in patients with cardiomyopathies (CMP). To achieve this objective, we plan first to test the hypothesis that patients with CMP present focal alterations in myocardial hyperpolarized \[1-13C\]pyruvate flux.
What is the current status of trial NCT03057002?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2018-05-01. Estimated completion is 2023-05-17.
What interventions are being tested in trial NCT03057002?
The interventions under investigation include: Hyperpolarized 13C-Pyruvate (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03057002?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.